Source comparison
TB-500 for Hair Regrowth Research: Peptide Comparison
TB-500 (Thymosin Beta-4) Actin polymerisation, angiogenesis, stem cell activation Mouse models show accelerated follicle cycling; no human RCTs for alopecia Subcutaneous injection 2–5mg 2x/week Promising preclinical data but lacks human clinical validation—bes
This comparison does not assign a generated winner or score.
- TB-500 (Thymosin Beta-4)
- Actin polymerisation, angiogenesis, stem cell activation
- Mouse models show accelerated follicle cycling; no human RCTs for alopecia
- Subcutaneous injection 2–5mg 2x/week
- Promising preclinical data but lacks human clinical validation—best positioned as adjunct to proven therapies
- GHK-Cu (Copper Peptide)
- Stimulates collagen synthesis, modulates 5-alpha reductase, anti-inflammatory
- Small human studies show increased hair density with topical application
- Topical serum 1–2% concentration daily
- More direct human evidence than TB-500 but effect size modest—works best combined with microneedling
- BPC-157
- Promotes VEGF expression, accelerates wound healing, reduces inflammation
- No published hair-specific studies; follicle benefit inferred from tissue repair data
- Subcutaneous injection 250–500mcg daily or topical
- Mechanistically plausible but zero hair regrowth trials—purely theoretical application
- Minoxidil
- Opens potassium channels in follicle cells, increases dermal papilla VEGF
- Extensive RCT evidence—FDA-approved for pattern hair loss since 1988
- Topical 5% solution twice daily
- Gold standard—proven efficacy but must be used indefinitely; discontinuation reverses gains
- TB-500 sits in a unique position: stronger mechanistic rationale than most experimental peptides but weaker clinical validation than FDA-approved options. For researchers designing protocols, it makes sense as a combination agent with minoxidil or microneedling—not as monotherapy.